CPC A61K 39/385 (2013.01) [A61K 9/127 (2013.01); A61K 9/14 (2013.01); A61K 9/51 (2013.01); A61K 9/5115 (2013.01); A61K 9/5146 (2013.01); A61K 9/5153 (2013.01); A61K 31/192 (2013.01); A61K 38/13 (2013.01); A61K 38/1816 (2013.01); A61K 38/38 (2013.01); A61K 39/00 (2013.01); A61K 39/001 (2013.01); A61K 39/0008 (2013.01); A61K 39/35 (2013.01); A61K 39/36 (2013.01); A61K 47/50 (2017.08); A61K 47/52 (2017.08); A61K 47/544 (2017.08); A61K 47/593 (2017.08); A61K 47/643 (2017.08); A61K 47/69 (2017.08); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 47/6937 (2017.08); B82Y 5/00 (2013.01); G01N 33/505 (2013.01); G01N 33/56972 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/577 (2013.01); B82Y 40/00 (2013.01); G01N 2333/7051 (2013.01); G01N 2333/70514 (2013.01); G01N 2333/70517 (2013.01); Y02A 50/30 (2018.01)] | 19 Claims |
1. A method comprising administering to a subject:
i) a composition comprising a first population of polymeric synthetic nanocarriers coupled to an immunosuppressant wherein the immunosuppressant is rapamycin or a rapamycin analog, and
ii) an APC presentable antigen,
wherein the load of immunosuppressant on average across the first population of polymeric synthetic nanocarriers is at least 2% but no more than 25% (weight/weight), and wherein at least 75% of the polymeric synthetic nanocarriers of the first population have a minimum dimension, obtained using dynamic light scattering, that is greater than 110 nm and a maximum dimension, obtained using dynamic light scattering, that is equal to or less than 500 nm, wherein the subject is in need of antigen-specific tolerance.
|